Morrow and Novacel Optical partner ahead of eProgressive smart glasses distribution


A strategic distribution partnership is expected to make Morrow’s eProgressive smart glasses available to consumers in the second quarter of 2024

A pair of glasses sits on a pile of Euro banknotes. Image credit: ©Tania –

The partnership will expand the availability of eProgressive smart glasses in Europe. Image credit: ©Tania –

Belgium-based vision technology firm Morrow and French lens manufacturer Novacel Optical have teamed up to take smart glasses to the next level.

The companies announced in a news release that they have entered a strategic distribution partnership for the launch of Morrow’s eProgressive smart glasses, which are designed to enhance vision with a switchable lens technology. The glasses will be available to consumers in the second quarter of the 2024 fiscal year.

“This collaboration exemplifies Novacel Optical’s consumer and optician-centric approach, dedicated to bringing the latest innovations to the eyewear market,” said Novacel Optical CEO Jenkiz Saillet.

Morrow’s eProgressive glasses work by mimicking natural eye accommodation with the push of a button. An electric current activates a liquid crystal lens in the glasses, which instantly changes light refraction. This allows the glasses to transition focus from near to far, and vice versa, eliminating the need for multiple pairs of progressive lenses. Instead of swapping between glasses, progressive wearers can transition from walking down the street to looking at their phone without taking their glasses off.

With the transition between vision focuses spanning a mere 0.6 seconds, eProgressive glasses provide a wider field of view, reduced side distortions, improved depth perception and heightened comfort. Morrow said this increase in comfort for its customers is indicative of the glasses’ Net Promoter Score of over 67, “signifying a high level of customer satisfaction.”1 Other benefits provided by eProgressive glasses include fewer aberrations, faster adaptation, no blurry bottom of lenses and an electronic boost for reading when near sight is turned on.1

In a news release, the company cited a popular dissatisfaction with bifocal and progressive lenses, with recent studies showing 26% of patients unsatisfied, and 13% struggling to adapt due to eye strain, reduced vision and peripheral issues. Morrow details loss of peripheral vision, limited field of view for reading, poor ergonomics during screen work and a higher risk of falling as the downsides to traditional progressive lenses.

The partnership allows Novacel Optical to gain exclusive access to Morrow’s technology for the French and Swiss markets, as Novacel is one of France’s main eyewear manufacturers.1

Ultimately, the collaborative goal of the companies is to provide improved vision and comfort for the over 30 million people with presbyopia in France and Switzerland, according to the news release.

“In a digital age, where everything evolves, glasses remained stuck in the past,” said Morrow CEO Paul Marchal in the company statement. “This agreement is the culmination of 7 years of tireless work. We finally bring true innovation and better vision to the market.”

Smart glasses utilising augmented reality (AR) technology have been cycling through both the consumer and industrial market for about a decade, with Google’s launch of Google Glass in 2013. Smart glasses have found more popularity in industrial use since their inception, as they work with the existing environment to superimpose information via the internet onto a field of vision. In embedded wireless glasses, this can be achieved via transparent heads-up display, see-through displays, or AR overlay.2

To learn more about eProgressive smart glasses, visit Morrow’s website.


  1. Morrow and Novacel Optical Partner to launch smart eProgressive glasses in France and Switzerland. Morrow. Press Release. Published January 15, 2024. Accessed January 16, 2024.
  2. Industrial augmented reality glasses: use case and applications. Acty. Updated 2023. Accessed January 16, 2024.
Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.